VIR_logo_large.jpg
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
20 juil. 2023 08h00 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
06 sept. 2022 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...